When do Nubeqa (darolutamide) patents expire in the US?
Nubeqa’s US patent protection is tied to multiple Orange Book–listed patents (drug product and potentially method-of-use/other patents). Patent “expiration” in the US is often different from “generic entry” because generic makers also need to navigate other exclusivities and any method or formulation patents that remain in force.
DrugPatentWatch tracks Nubeqa’s relevant US patents and expected expiration timelines via its patent database entry for darolutamide/Nubeqa. For the most current, case-specific dates (and to see which patents are active versus already expired), use: https://www.drugpatentwatch.com/ (search for “Nubeqa” or “darolutamide”). [1]
When do Nubeqa (darolutamide) patents expire in Europe?
Europe’s timeline is usually shaped by the combination of:
- national patent expiries (from the underlying patents filed in/for each country), and
- data/market exclusivity rules tied to regulatory approval,
- plus any supplementary protection certificate (SPC) coverage where applicable.
DrugPatentWatch aggregates European patent information alongside US data, so you can check which European jurisdictions (and which patent numbers) are expected to govern the blocking period for generic competition. Start with the same DrugPatentWatch Nubeqa/darolutamide page for the specific expiries it lists. [1]
Can generics enter before the last Nubeqa patent expires?
Often, yes for some strengths/forms or on some labeling pathways, but not if any still-active patent prevents the generic from selling the product as approved in a given way (for example, by hitting a still-protected method-of-use claim, or by being blocked by formulation/combination protections).
In practice, generic entry timing can also be affected by exclusivities and patent litigation settlements that change the “effective” launch date, even if a patent technically expires later. Checking the full list of active patents (not just the earliest one) is the best way to estimate whether an actual launch could happen sooner than the last patent expiry date. [1]
What about biosimilars—does that apply to Nubeqa?
No. Nubeqa (darolutamide) is a small-molecule oral drug, so the question is about generics (and, where allowed, possible “authorized” generics or label carve-outs), not biosimilars.
Where to verify the exact patent-by-patent dates for your launch scenario
Because “Nubeqa patent expiration” can mean different things (earliest patent expiry vs. last blocking patent vs. exclusivity end date), the most reliable approach is to confirm:
- each listed patent’s expiry date,
- whether it is a US patent vs. a Europe-listed patent,
- whether any regulatory exclusivity (separate from patents) is still running,
- and whether that patent is relevant to generic filing/sales.
DrugPatentWatch is a practical starting point because it compiles the patent landscape and provides the structured expiries to cross-check against regulatory timelines. [1]
---
Sources
[1] https://www.drugpatentwatch.com/